Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386723 · ClinicalTrials.gov registry record
End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 35
- Enrollment target
NCT01386723: Clinical Trial study, sponsored by Weill Medical College of Cornell University.
NCT01386723 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01386723 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 35 participants
- Enrollment target
Study Summary
This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months. This requires that if patients stop treatment with eltrombopag, they are not immediately transitioned to further treatment unless it is necessary. The objective of the study is to assess how frequently patients who have discontinued eltrombopag attain a stable, treatment-free, unmaintained adequate platelet count 4 to 8 weeks after discontinuing eltrombopag and how long such a response lasts (if it occurs).
Primary Outcome
To determine the frequency of a sustained response of at least 6 months in subjects with persistent or chronic ITP who have been receiving eltrombopag for a minimum of four months and are able to discontinue it within two years of initiating the tapering
Interventions
- DRUG Discontinuation of eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-06 |
Why NCT01386723 stopped before completion
NCT01386723 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Discontinuation of eltrombopag is the first listed.
NCT01386723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01386723 about?
NCT01386723 is a clinical study titled "End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia". This study proposes to observe whether a stable platelet count would be maintained without additional treatment in the long term in at least a proportion of patients who have discontinued eltrombopag taken for at least 4 months. This requires that if patients stop treatment with eltrombopag, they ar...
What is the current status of trial NCT01386723?
This trial is currently terminated. The enrollment target is 35 participants. The study started on 2011-06.
What interventions are being tested in trial NCT01386723?
The interventions under investigation include: Discontinuation of eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01386723?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia